Du X X, Neben T, Goldman S, Williams D A
Herman B Wells Center for Pediatric Research, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis 46202-5225.
Blood. 1993 Jan 1;81(1):27-34.
We have examined the effects of recombinant human interleukin-11 (rhIL-11) on the recovery of peripheral blood cell counts and proliferation of progenitors and hematopoietic stem cells (day 12 colony-forming units-spleen-CFU-S12) in vivo using a mouse bone marrow (BM) and spleen cell transplantation model. Recovery of leukocytes was accelerated in animals receiving daily administration of rhIL-11 (100 micrograms/kg/d) and reached normal levels by day 14 posttransplantation. This increased total leukocyte count reflected mainly an increase in neutrophils. Neutropenia (absolute neutrophil count [ANC] < 1,500) was present in control transplant mice for 14 to 15 days, while in the rhIL-11-treated group, neutrophils recovered to normal by days 8 to 10 and continued to increase until day 19. Animals treated with rhIL-11 had only 1 day with ANC demonstrated < 500. Correspondingly, rhIL-11 treatment increased granulocyte-macrophage progenitors (CFU-GM) derived from both spleen and BM cells. Higher doses of IL-11 increased CFU-GM nearly threefold and CFU-Mix fourfold to fivefold, while increasing burst-forming units-erythroid to a lesser degree. BM and spleen cellularity were both increased in IL-11-treated mice, but no increase in CFU-S12 was noted. In addition, in vivo daily administration of IL-11 increased peripheral platelet counts by threefold over control transplant mice at day 10 posttransplantation during the post-irradiation platelet nadir. Further treatment led to platelet counts higher than normal 18 days posttransplantation when control animals had just attained normal platelet counts. IL-11 can accelerate the recovery of the peripheral blood leukocytes, mainly neutrophils, and platelets in transplant mice, effects that may be clinically useful in future applications for BM transplantation and chemotherapy-related cytopenias.
我们使用小鼠骨髓(BM)和脾细胞移植模型,在体内研究了重组人白细胞介素-11(rhIL-11)对外周血细胞计数恢复以及祖细胞和造血干细胞增殖(第12天脾集落形成单位-CFU-S12)的影响。接受每日rhIL-11(100微克/千克/天)给药的动物白细胞恢复加速,移植后第14天达到正常水平。总白细胞计数增加主要反映了中性粒细胞的增加。对照移植小鼠中存在中性粒细胞减少症(绝对中性粒细胞计数[ANC]<1500)达14至15天,而在rhIL-11治疗组中,中性粒细胞在第8至10天恢复正常并持续增加直至第19天。接受rhIL-11治疗的动物只有1天ANC显示<500。相应地,rhIL-11治疗增加了源自脾细胞和BM细胞的粒细胞-巨噬细胞祖细胞(CFU-GM)。更高剂量的IL-11使CFU-GM增加近三倍,CFU-Mix增加四倍至五倍,而对红系爆式集落形成单位的增加程度较小。IL-11治疗的小鼠BM和脾细胞密度均增加,但未观察到CFU-S12增加。此外,在体内每日给予IL-11可使移植后第10天照射后血小板最低点时的外周血小板计数比对照移植小鼠增加三倍。进一步治疗导致移植后18天血小板计数高于正常水平,而此时对照动物刚刚达到正常血小板计数。IL-11可加速移植小鼠外周血白细胞(主要为中性粒细胞)和血小板的恢复,这些作用在未来骨髓移植和化疗相关血细胞减少症的临床应用中可能有用。